The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

blonca9
Nov 7, 2023
1 min read

Raphaël Ognar discusses the results we have seen in the NK space over recent years and how NKILT is targeting a novel pathway with its Chimeric ILT-Receptor (CIR) binding technology.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight